Cargando…

Repurposing Infectious Diseases Vaccines Against Cancer

Vaccines used to prevent infections have long been known to stimulate immune responses to cancer as illustrated by the approval of the Bacillus Calmette–Guérin (BCG) vaccine to treat bladder cancer since the 1970s. The recent approval of immunotherapies has rejuvenated this research area with report...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandeborne, Liese, Pantziarka, Pan, Van Nuffel, An M. T., Bouche, Gauthier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155725/
https://www.ncbi.nlm.nih.gov/pubmed/34055652
http://dx.doi.org/10.3389/fonc.2021.688755
_version_ 1783699271249297408
author Vandeborne, Liese
Pantziarka, Pan
Van Nuffel, An M. T.
Bouche, Gauthier
author_facet Vandeborne, Liese
Pantziarka, Pan
Van Nuffel, An M. T.
Bouche, Gauthier
author_sort Vandeborne, Liese
collection PubMed
description Vaccines used to prevent infections have long been known to stimulate immune responses to cancer as illustrated by the approval of the Bacillus Calmette–Guérin (BCG) vaccine to treat bladder cancer since the 1970s. The recent approval of immunotherapies has rejuvenated this research area with reports of anti-tumor responses with existing infectious diseases vaccines used as such, either alone or in combination with immune checkpoint inhibitors. Here, we have reviewed and summarized research activities using approved vaccines to treat cancer. Data supporting a cancer therapeutic use was found for 16 vaccines. For 10 (BCG, diphtheria, tetanus, human papillomavirus, influenza, measles, pneumococcus, smallpox, typhoid and varicella-zoster), clinical trials have been conducted or are ongoing. Within the remaining 6, preclinical evidence supports further evaluation of the rotavirus, yellow fever and pertussis vaccine in carefully designed clinical trials. The mechanistic evidence for the cholera vaccine, combined with the observational data in colorectal cancer, is also supportive of clinical translation. There is limited data for the hepatitis B and mumps vaccine (without measles vaccine). Four findings are worth highlighting: the superiority of intravesical typhoid vaccine instillations over BCG in a preclinical bladder cancer model, which is now the subject of a phase I trial; the perioperative use of the influenza vaccine to limit and prevent the natural killer cell dysfunction induced by cancer surgery; objective responses following intratumoral injections of measles vaccine in cutaneous T-cell lymphoma; objective responses induced by human papillomavirus vaccine in cutaneous squamous cell carcinoma. All vaccines are intended to induce or improve an anti-tumor (immune) response. In addition to the biological and immunological mechanisms that vary between vaccines, the mode of administration and sequence with other (immuno-)therapies warrant more attention in future research.
format Online
Article
Text
id pubmed-8155725
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81557252021-05-28 Repurposing Infectious Diseases Vaccines Against Cancer Vandeborne, Liese Pantziarka, Pan Van Nuffel, An M. T. Bouche, Gauthier Front Oncol Oncology Vaccines used to prevent infections have long been known to stimulate immune responses to cancer as illustrated by the approval of the Bacillus Calmette–Guérin (BCG) vaccine to treat bladder cancer since the 1970s. The recent approval of immunotherapies has rejuvenated this research area with reports of anti-tumor responses with existing infectious diseases vaccines used as such, either alone or in combination with immune checkpoint inhibitors. Here, we have reviewed and summarized research activities using approved vaccines to treat cancer. Data supporting a cancer therapeutic use was found for 16 vaccines. For 10 (BCG, diphtheria, tetanus, human papillomavirus, influenza, measles, pneumococcus, smallpox, typhoid and varicella-zoster), clinical trials have been conducted or are ongoing. Within the remaining 6, preclinical evidence supports further evaluation of the rotavirus, yellow fever and pertussis vaccine in carefully designed clinical trials. The mechanistic evidence for the cholera vaccine, combined with the observational data in colorectal cancer, is also supportive of clinical translation. There is limited data for the hepatitis B and mumps vaccine (without measles vaccine). Four findings are worth highlighting: the superiority of intravesical typhoid vaccine instillations over BCG in a preclinical bladder cancer model, which is now the subject of a phase I trial; the perioperative use of the influenza vaccine to limit and prevent the natural killer cell dysfunction induced by cancer surgery; objective responses following intratumoral injections of measles vaccine in cutaneous T-cell lymphoma; objective responses induced by human papillomavirus vaccine in cutaneous squamous cell carcinoma. All vaccines are intended to induce or improve an anti-tumor (immune) response. In addition to the biological and immunological mechanisms that vary between vaccines, the mode of administration and sequence with other (immuno-)therapies warrant more attention in future research. Frontiers Media S.A. 2021-05-13 /pmc/articles/PMC8155725/ /pubmed/34055652 http://dx.doi.org/10.3389/fonc.2021.688755 Text en Copyright © 2021 Vandeborne, Pantziarka, Van Nuffel and Bouche https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Vandeborne, Liese
Pantziarka, Pan
Van Nuffel, An M. T.
Bouche, Gauthier
Repurposing Infectious Diseases Vaccines Against Cancer
title Repurposing Infectious Diseases Vaccines Against Cancer
title_full Repurposing Infectious Diseases Vaccines Against Cancer
title_fullStr Repurposing Infectious Diseases Vaccines Against Cancer
title_full_unstemmed Repurposing Infectious Diseases Vaccines Against Cancer
title_short Repurposing Infectious Diseases Vaccines Against Cancer
title_sort repurposing infectious diseases vaccines against cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155725/
https://www.ncbi.nlm.nih.gov/pubmed/34055652
http://dx.doi.org/10.3389/fonc.2021.688755
work_keys_str_mv AT vandeborneliese repurposinginfectiousdiseasesvaccinesagainstcancer
AT pantziarkapan repurposinginfectiousdiseasesvaccinesagainstcancer
AT vannuffelanmt repurposinginfectiousdiseasesvaccinesagainstcancer
AT bouchegauthier repurposinginfectiousdiseasesvaccinesagainstcancer